TRIlogy-5
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 700 patients (estimated)
- Sponsors
- Johnson & Johnson
- Tags
- Trispecific Antibody, T Cell Engager (TCE), GPRC5D, B-Cell Maturation Antigen (BCMA), Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2264
- NCT Identifier
- NCT07518186
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.